Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDL BioPharma Plans To Divest Assets, Emerge As Pure Play Biotech

This article was originally published in The Pink Sheet Daily

Executive Summary

Sale of PDL’s lucrative royalty stream or even the company itself is not off the table as reorganization unfolds.

You may also be interested in...



PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan

In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.

PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan

In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.

PDL Now Says It Will Consider Sale Of Entire Company

CEO McDade formally steps down, while former board chairman Gage becomes interim CEO.

Related Content

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel